ABDOMINAL AORTIC ANEURYSM (AAA)

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)
Last reviewed: October 2026

I DEFINITION, CLASSIFICATION AND BIOMECHANICS (ESC 2024 PAAD / ACC-AHA 2022 AORTIC GUIDELINES)

- **Definition:** An Abdominal Aortic Aneurysm (AAA) is a permanent, localized, full-thickness (true) dilatation of the abdominal aorta to an **anteroposterior (AP) diameter of 30 mm (3.0 cm) or greater**, or **greater than 1.5 times (50 percent increase over)** the expected normal contiguous segment diameter. (Aortic diameters between 25 and 29 mm are termed **aortic ectasia**.)
- **Anatomical Classification (Relative to Renal Arteries):**
  - **Infrarenal AAA (~85%):** Originates at least **10 mm (1.0 cm) distal** to the lowest renal artery (providing an adequate proximal "neck" for endovascular stent-graft sealing).
  - **Juxtarenal AAA (~10%):** Extends up to the lower margin of the renal arteries (proximal neck <10 mm) without directly involving the renal ostia.
  - **Pararenal and Suprarenal AAA (~5%) / Type IV Thoracoabdominal Aortic Aneurysm:** Involves the origin of one or both renal arteries (pararenal) or extends above the renal arteries to involve the superior mesenteric and celiac arteries (suprarenal).
  - **The Law of Laplace and Rupture Biomechanics:** Circumferential **Wall Tension (T) = (Transmural Pressure [P] x Radius [r]) / Wall Thickness (w)**. As the radius enlarges and the medial wall thins, wall stress increases linearly; rupture occurs when local biomechanical **Peak Wall Stress** exceeds the tensile strength of the adventitial collagen network.

II PATHOGENESIS (CELLULAR TO STRUCTURAL)

- **Extracellular Matrix (ECM) Proteolytic Degradation:** Driven by an imbalance between upregulated **Matrix Metalloproteinases**—specifically **MMP-9 (Gelatinase B, secreted by infiltrating macrophages)** and **MMP-2 (Gelatinase A, secreted by mesenchymal/smooth muscle cells)**, alongside cathepsins S and K—and downregulated **Tissue Inhibitors of Metalloproteinases (TIMP-1, TIMP-2)**. **Elastin fragmentation** initiates aortic dilatation, whereas **Type I and III adventitial collagen degradation** precipitates acute aortic rupture.
- **Transmural Chronic Inflammation and Oxidative Stress:** Dense infiltration of the outer media and adventitia by **M1 macrophages, CD4+ T-lymphocytes (Th1/Th2/Th17), B-cells, mast cells, and neutrophils** secreting **IL-1beta, IL-6, TNF-alpha, IFN-gamma**, and reactive oxygen species.
- **Vascular Smooth Muscle Cell (VSMC) Apoptosis and Senescence:** Profound depletion and phenotypic switching of medial VSMCs prevent synthesis and repair of new elastin and collagen fibers.
- **Intraluminal Thrombus (ILT) and Infrarenal Anatomical Vulnerability:**
  - **Unique Infrarenal Susceptibility:** Compared with the thoracic aorta, the infrarenal abdominal aorta has a **lower elastin-to-collagen ratio**, an **avascular media devoid of nutrient vasa vasorum** (relying on luminal diffusion), and amplified **oscillatory shear stress / pressure wave reflections** from the iliac bifurcation.
  - **Biologically Active Intraluminal Thrombus:** Mural thrombus lining the aneurysm sac traps **neutrophils and plasmin**, releasing proteases and creating severe **localized medial wall hypoxia** beneath the thick thrombus that accelerates wall weakening.
  - **Crucial Paradoxical Epidemiological Risk Factor — The Diabetes Mellitus Paradox:** While **cigarette smoking** (strongest modifiable risk factor; odds ratio >5), male sex (4:1 to 6:1 over women, though women rupture at smaller diameters), age >65 years, hypertension, and family history strongly promote AAA, **Diabetes Mellitus is consistently associated with a 30 to 50 percent LOWER incidence and slower growth rate of AAA** (attributed to advanced glycation end-product [AGE] cross-linking of medial collagen and metformin-mediated suppression of MMP/inflammation).

III CLINICAL PRESENTATION AND DIAGNOSTIC IMAGING

- **Clinical Presentation:**
  - **Asymptomatic (75 to 80 percent):** Detected incidentally on abdominal imaging or via population ultrasound screening.
  - **Symptomatic Intact AAA (Impending Rupture):** New or worsening deep, constant **abdominal, lower back, or flank pain** (often mimicking renal colic or lumbar disc disease) with tenderness on palpation over a pulsatile epigastric/umbilical mass.
  - **Ruptured AAA (Classic Triad): Sudden severe abdominal/back pain + pulsatile abdominal mass + hypotension/syncope** (present in complete form in only 30 to 50 percent; retroperitoneal containment may temporarily tamponade bleeding—"contained rupture").
  - **Distal Atherothrombotic Embolization ("Blue Toe Syndrome"):** Cholesterol crystals or mural microthrombi embolize to digital arteries with preserved pedal pulses.
  - **Abdominal Duplex Ultrasound (DUS — Class I Screening & Surveillance Standard):** Sensitivity and specificity >95%; **2024 ESC Guidelines** specify measuring the maximum **anteroposterior (AP) diameter perpendicular to the longitudinal axis of the aorta** using a consistent caliper convention (**Outer-to-Outer [OTO] or Leading-Edge-to-Leading-Edge [LELE]**; note that **Inner-to-Inner [ITI]** used in the UK MASS trial measures ~2 to 4 mm smaller than OTO).
  - **Contrast-Enhanced CT Angiography (CTA — Class I Gold Standard for Pre-Intervention Planning & Symptomatic/Ruptured AAA):** Thin-slice ECG-gated or helical CTA from the thorax to the femoral arteries with **3D centerline reconstruction** defines **EVAR anatomical suitability** and detects **signs of impending rupture** (**Hyperattenuating Crescent Sign** [acute hemorrhage into the mural thrombus/wall], **draped aorta sign**, focal wall discontinuity/bleb, and periaortic fat stranding).

Clinical / Anatomical Parameter	Guideline Threshold (ESC 2024 / ACC-AHA 2022)	Clinical Action / Recommendation
Population DUS Screening	Men **>=65 yr** (Class I); women **>=65 yr** with a smoking history may be considered; first-degree relatives **>=50 yr** should be considered	One-time Abdominal Duplex Ultrasound
Surveillance Intervals by Diameter	**30–39 mm:** Every **3 years**; **40–49 mm** (40–44 mm in women): Every **1 year**; **50–54 mm** (45–49 mm in women): Every **3–6 months**	Serial DUS (switch to CTA when approaching repair threshold)
Elective Repair Thresholds	**>=55 mm in Men** (**Class I**); **>=50 mm in Women** (**Class IIa**); **Rapid growth >=5 mm in 6 months or >=10 mm/year**; or **Saccular AAA**	Elective **EVAR** (if anatomy suitable & reasonable life expectancy >2 yr) or **Open Surgical Repair**

Clinical / Anatomical Parameter	Guideline Threshold (ESC 2024 / ACC-AHA 2022)	Clinical Action / Recommendation
Symptomatic or Ruptured AAA	**Any diameter** with aneurysm-related pain or rupture	**Emergency Repair (Class I): EVAR preferred over Open Repair** for ruptured AAA if anatomically suitable (**IMPROVE Trial**)
Small Asymptomatic AAA (<55 mm M / <50 mm F)	**30 to 54 mm** without symptoms or rapid growth	**Early repair is Class III (No Benefit)** (**UKSAT, ADAM, CAESAR, PIVOTAL Trials**)

IV MANAGEMENT: MEDICAL, ENDOVASCULAR (EVAR) VS. OPEN SURGERY, AND ENDOLEAKS

- **Medical Optimization (Class I):** Immediate **smoking cessation** (the single most effective intervention to slow AAA growth rate), **High-Intensity Statin**, **Antihypertensive control (target SBP 120 to 129 mmHg)**, and single antiplatelet therapy if concomitant ASCVD is present. (**Crucial Guideline Pitfall: Fluoroquinolone antibiotics [Ciprofloxacin, Levofloxacin] are Class III Contraindicated / Avoided** in patients with aortic aneurysms because they upregulate MMPs and double the acute risk of aortic dissection and rupture; also note that randomized trials of **Doxycycline [N-TA3CT Trial]** and beta-blockers failed to slow small AAA growth.)
- **Endovascular Aneurysm Repair (EVAR) vs. Open Surgical Repair (OSR):**
  - **Standard EVAR Anatomical Criteria (Instructions for Use [IFU]):** Proximal infrarenal neck length **>=10 to 15 mm**, neck diameter **<=32 mm**, infrarenal neck angulation **<60 degrees**, minimal circumferential neck thrombus/calcium, and adequate iliofemoral access (**>=7 mm**). (Juxtarenal/pararenal AAAs require **Fenestrated/Branched EVAR [FEVAR/BEVAR]** or Open Repair.)
  - **Landmark Randomized Trials (EVAR-1, DREAM, OVER, ACE Trials):** Consistently proved that **EVAR reduces 30-day perioperative mortality by ~65 to 70 percent (~1.2–1.7% vs. ~4.2–4.7% with Open Repair)** and shortens hospital stay; however, **this early survival advantage is lost by 2 to 4 years**, and at **15-year follow-up of EVAR-1 (*Lancet* 2016)**, EVAR had **higher late aneurysm-related mortality and secondary re-intervention rates** driven by late **Endoleaks** and sac rupture.
  - **Lifelong Post-EVAR Surveillance (Class I):** Baseline CTA + DUS at 1 month, followed by lifelong serial DUS/CTA to detect stent migration or **Endoleaks (Types I to V)**:
  - **Type I Endoleak (High-Pressure — Mandatory Urgent Repair, Class I):** Inadequate seal at the **proximal (Type Ia)** or **distal (Type Ib)** attachment site (or iliac occluder, **Type Ic**).
  - **Type II Endoleak (Most Common ~20–25% — Low-Pressure):** Retrograde collateral backbleeding into the sac via a patent **Inferior Mesenteric Artery (Type IIa)** or **Lumbar Arteries (Type IIb)**; observe unless the **aneurysm sac expands by >=5 to 10 mm**, which then warrants transcatheter coil/glue embolization.
  - **Type III Endoleak (High-Pressure — Mandatory Urgent Repair, Class I):** Structural graft defect—**component modular disconnection (Type IIIa)** or **fabric tear/hole (Type IIIb)**.
  - **Type IV Endoleak:** Graft fabric porosity (self-limiting within 30 days of implant).
  - **Type V Endoleak ("Endotension"):** Progressive sac expansion without a demonstrable endoleak on imaging.

KEY REFERENCES

- **Mazzolai L, Teixido-Tura G, Lanzi S, et al.:** 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases, *European Heart Journal*, 2024.
- **Isselbacher EM, Preventza O, Hamilton Black J III, et al.:** 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease, *Circulation*, 2022.
- **Patel R, Sweeting MJ, Powell JT, Greenhalgh RM (EVAR Trial Investigators):** Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial, *The Lancet*, 2016.